Governor calls Eisai building a testament to company's success
Eisai dedicates new corporate headquarters
Pharmaceutical executives, local politicians, Japanese dignitaries, and Eisai Corp. employees braved a steady, clammy drizzle on Wednesday to dedicate the company's new corporate headquarters. More than 300 people attended a ribbon-cutting ceremony for the $75 million, three-story building, including Gov. Jon S. Corzine; Motoatsu Sakurai, ambassador and Consul General of Japan in New York; and Billy Tauzin, president and CEO of PhRMA. The building, constructed in 13 months and located in Woodcliff Lake, N.J., can accommodate 700 employees and features video conferencing rooms. "Today, we celebrate a new headquarters that will help produce some great new medicines," Tauzin said. Corzine called the opening a "great day for the state of New Jersey" and promised to work with Eisai Corp. of North America and Eisai Inc. to meet its business goals. "Thank you for making a commitment to the state of New Jersey," he said. Soichi Matsuno, deputy president/representative executive officer, Global Pharmaceuticals Business, Global Human Resources for Tokyo-based Eisai Co., said the company's American business operation is a key driver to worldwide growth. Eisai, he added, has plans to expand its operations into Brazil, Canada, and Mexico in the near future. Eisai, which reported sales of $2.6 billion for the 2006 fiscal year, relocated its headquarters from Teaneck, N.J., earlier this year.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
